Note 7 - Statera License Agreement (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Milestone Payments [Table Text Block]

Event	Payment
Validation of current inventory of Materials for distribution and sales	$	750,000
Filing of BLA with FDA for Acute Radiation Syndrome		1,000,000
Total Acute Radiation Syndrome Development Milestones	$	1,750,000

Event	Payment
File IND and Initiate Phase 2 Clinical Study for Neutropenia	$	500,000
Phase III Completion - successfully meets endpoint required to secure FDA approval for treatment of Neutropenia		750,000
File BLA with FDA and achieve FDA Approval for Neutropenia		1,500,000
File IND and Initiate Phase 2 study of Lymphocyte Exhaustion		500,000
Phase III Completion - successfully meets endpoint required by FDA for treatment of Lymphocyte Exhaustion		750,000
File BLA with FDA and achieve FDA Approval for Lymphocyte Exhaustion		1,500,000
IND approval and initiation of Phase 3 study as a Vaccine Adjuvant		500,000
File US BLA with FDA and achieve FDA Approval for use as a Vaccine Adjuvant		500,000
Total Potential Development Milestones for additional Indications (as applicable)	$	6,500,000